California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. The proceeds will support ...

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced the closing of a $35 million ...

Single-cell analysis revealed the molecular triggers that drive stem cells to become cancerous, which may help inform ...

Vivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...

It has long been understood that the Hippo pathway plays a critical role in the development of a wide range of diseases. Although once seen as an elusive pathway, emerging novel data and research ...

Since only a few PI5P4K regulators were known, the research team screened 29 other potential regulators and found two—core ...

Hippo signalling is a cell signalling pathway that controls organ size. Activation of Hippo results in a series of phosphorylation events that culminate in the phosphorylation and cytoplasmic ...

Two seemingly disparate signaling pathways -- one that controls organ size in fruit ... to restrict cell proliferation and control heart size. Wild-type (left) and Hippo mutant (right) neonate mouse ...